补骨胶囊治疗SLE患者骨质疏松症的作用机制

Mechanism of bugu capsule in treatment of osteoporosis in systemic lupus erythromatosus

目的研究补骨胶囊防治系统性红斑狼疮(SLE)患者长期使用糖皮质激素治疗并发骨质疏松或骨量减少的作用机制。方法66例SLE患者随机分为两组,治疗组(34例)采用糖皮质激素和补骨胶囊治疗,对照组(32例)采用糖皮质激素治疗,分析两组患者治疗前后血清血钙(Ca)、血磷(P)、血清碱性磷酸酶(ALP)和血甲状旁腺素(Parathyroid hormone,PTH)的变化,并对三角区(Ward’s)等进行了骨密度(Bone mineral density,BMD)的测定。结果治疗组治疗前后血Ca、P、ALP和PTH差异无统计学意义,对照组血Ca和PTH的表达差异有统计学意义(P<0·01)。治疗组患者骨质疏松或骨量减少的发生率明显低于对照组(P<0·05)。结论补骨胶囊治疗SLE患者骨质疏松或骨量减少的机制可能是通过恢复SLE患者体内血Ca和PTH的平衡紊乱。

Objective To investigate the mechanism of Bugu capsules in the treatment of osteoporosis or bone loss in systemic lupus erythematosus（SLE） patients after long - term administration of glucocorticoid. Methods Sixty - six cases with SLE were divided into two groups randomly. Treatment group consisted of 54 cases were treated with glucocorticoid and Bugn capsules and control group consisted of 52 cases were treated with glucocorticoid. All patients were evaluated by determination of bone mineral density （BMD） and related biochemical parameters such as serum calcium, serum P, serum ALP and serum parathyroid hormone（PTH） before and after treatment. Results The changes of concentrations of serum calcium, serum P, serum ALP and serum PTH between pre - treatment and post - treatment in treatment group were no significant （ P 〉 0.05 ）. The changes of concentrations of serum calcium and serum PTH between pre - treatment and post- treatment in control group were significant （P 〈 0.01 ）. Osteoporosis or bone loss rate in treatment group was significant lower than that of control group （ P 〈 0.05 ）. Conclusion Mechanism of Bugn capsules in the treatment of osteoporosis and bone loss in SLE patients may be the regulation of the expression of serum Ca and serum PTH.